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London School of Hygiene & Tropical Medicine, Department of Clinical Research, Keppel Street, London, UKThe Non-Speciﬁc Effects (NSE) of vaccines refers to any other effect
of a given vaccine, other than the intended effect of reducing disease
from the speciﬁc vaccination. This area of public health has received a
large amount of attention in recent years, with arguments on both
sides suggesting that vaccines have either beneﬁcial or detrimental
NSE. So, where did it all start, what does it all mean and how does the
present study contribute to our understanding of this complex and
emotive issue?
Some of the ﬁrst evidence of the NSE of vaccines came from a group
in Guinea-Bissau studying the introduction of a high titer measles virus
into the WHO's Expanded Programme on Immunization (EPI) vaccine
schedule (Aaby et al., 1993a; Aaby et al., 1993c). The authors conducted
a randomised controlled trial to determine if high titer measles virus
(MV), given at 4–6 months, was as effective as the standard MV dose
that was being routinely given at 9 months of age. It was, but subse-
quent studies noted that therewas a twofold highermortality rate in in-
fants given the high titer MV vaccine, and that this effect was seen only
in girls, and not boys (Aaby et al., 1993b). It is important to note that
both of the MV vaccines are live, attenuated vaccines. Subsequent anal-
ysis (Aaby et al., 2003) suggested that the sex-speciﬁc mortality associ-
ated with high titer MV was due, not to the MV vaccine itself, but the
later administration of non-live vaccines, such as the combination vac-
cine Diphtheria/Pertussis/Tetanus (DPT). Recently, the same group has
reanalysed survival data from a more recently developed non-live vac-
cine, the anti-malarial vaccine, RTS,S (Klein et al., 2016). The data pre-
sented in this analysis would also suggest that if the last vaccine you
are given is a non-live vaccine (DPT or RTS,S for example), then there
is a higher mortality rate in females receiving these vaccines than if
you were given a live vaccine as the last vaccine. There appears to be
no deleterious NSE for any vaccine in males.
But things are not as bad as they seem. The same group fromGuinea-
Bissau has shown that if another live vaccine, BCG, is given at the time of
birth to underweight babies, there is a signiﬁcant decrease in all-cause
mortality in the ﬁrst four weeks of life (Aaby et al., 2011). Others have
shown that BCG confers a non-speciﬁc beneﬁt in adults given inﬂuenza
vaccination (Leentjens et al., 2015), likely in a process known as
“trained innate immunity” (Saeed et al., 2014). It is not currently clear
how the deleterious effects of non-live vaccines interrupt the beneﬁcial
effects of live vaccines, butmore clearly needs to be done to understand
these phenomena.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.07.012.
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save lives, andmillions of them every yearwhere they are administered.
One could make the argument that if mortality rates due to the NSE of
vaccines are low enough (but nevertheless twofold higher in females),
then there is still a population beneﬁt in giving vaccines. In other
words, if the vaccine saves more lives by preventing death from disease
than it does by causing a death, then there is a population beneﬁt in giv-
ing vaccines. But this does not help the parent whose otherwise healthy
child has just died from having been administered a vaccine known to
induce higher rates of mortality. One might reasonably ask then, given
the above evidence, whether we shouldn't be giving non-live vaccines
in a sequence where the last vaccine to be given is a live vaccine. Or
co-administration of non-live and live vaccines. This is where the pres-
ent study in this issue of EBioMedicine comes in (Aaby et al., 2017).
In the current study, the authors reanalysed historic data from
37,984 children born in Bangladesh between 1986 and 1999. Although
the WHO recommendation is BCG at birth, followed by other EPI vac-
cines (such as DPT) at later time points, in many areas of the world
BCG is co-administered with other vaccines. The authors found that
where BCG was given along with DPT, all-cause mortality was reduced
even further than when BCG alone was given. This is a striking ﬁnding,
and suggests that co-administration of a live vaccine (such as BCG)with
a non-live vaccine (such as DPT)might reverse the deleterious effects of
the non-live vaccine.
As stated above, vaccines save lives. However, this study highlights
just how much we don't know about the NSE of vaccines, how they in-
teract when live and non-live vaccines are given together, and indeed
whether the current EPI schedule is the best schedule for our global in-
fant population. The WHO itself states that more studies need to be
done to understand these effects (WHO, 2014), and this study serves
to throw these issues back into the spotlight again.
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